Triarylmethane analogs and their use in treating cancers
US-9358226-B2 · Jun 7, 2016 · US
Nanocarrier therapy for treating invasive tumors
US9872834B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9872834-B2 |
| Application number | US-201514980578-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 28, 2015 |
| Priority date | Apr 22, 2009 |
| Publication date | Jan 23, 2018 |
| Grant date | Jan 23, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition for treating tumors in a patient, comprising unilamellar liposomes containing a therapeutic amount of imipramine blue, or a pharmaceutically-acceptable salt thereof, in a pharmaceutically-acceptable carrier for intraveneous administration, wherein the liposomes comprise chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms. 2. The composition of claim 1 , wherein the liposomes have a size of from about 50 to about 160 nanometers. 3. The composition of claim 1 , wherein the phospholipids are synthetic phospholipids. 4. The composition of claim 1 , wherein the phospholipids comprise distearoylphosphatidyl choline. 5. The composition of claim 1 , wherein the phospholipids comprise a pegylated phospholipid. 6. The composition of claim 1 , wherein the phospholipids comprise DSPC, DSPE-PEG, and cholesterol. 7. The composition of claim 6 , wherein the ratio of DSPC/DSPE-PEG/cholesterol is about 85%/about 5%/about 10%. 8. The composition of claim 1 , further comprising an anti-tumor agent other than imipramine blue.
Assignees
Inventors
Classifications
- A61K9/1271Primary
Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Antineoplastic agents · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9872834B2 cover?
- Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and…
- Who is the assignee on this patent?
- Univ Emory, Georgia Tech Res Inst, Children'S Healthcare Of Atlanta Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/1271. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).